The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double‐blind, randomized, controlled trial
Abstract
Objective: A 12‐month double‐blind sham‐surgery–controlled trial assessing adeno‐associated virus type 2 (AAV2)‐neurturin injected into the putamen bilaterally failed to meet its primary endpoint, but showed positive results for the primary endpoint in the subgroup of subjects followed for 18 months and for several secondary endpoints. Analysis of postmortem tissue suggested impaired axonal transport of neurturin from putamen to substantia nigra. In the present study, we tested the safety and efficacy of AAV2‐neurturin delivered to putamen and substantia nigra. Methods: We performed a 15‐ to 24‐month, multicenter, double‐blind trial in patients with advanced Parkinson disease (PD) who were randomly assigned to receive bilateral AAV2‐neurturin injected bilaterally into the substantia nigra (2.0 × 10 11 vector genomes) and putamen (1.0 × 10 12 vector genomes) or sham surgery. The primary endpoint was change from baseline to final visit performed at the time the last enrolled subject completed the 15‐month evaluation in the motor subscore of the Unified Parkinson's Disease Rating Scale in the practically defined off state. Results: Fifty‐one patients were enrolled in the trial. There was no significant difference between groups in the primary endpoint (change from baseline: AAV2‐neurturin, −7.0 ± 9.92; sham, −5.2 ± 10.01; p = 0.515) or in most secondary endpoints. Two subjects had cerebral hemorrhages with transient symptoms. No clinically meaningful adverse events were attributed to AAV2‐neurturin. Interpretation: AAV2‐neurturin delivery to the putamen and substantia nigra bilaterally in PD was not superior to sham surgery. The procedure was well tolerated, and there were no clinically significant adverse events related to AAV2‐neurturin. Ann Neurol 2015;78:248–257
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease
Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., Halliday, G. M., & Bartus, R. T. (2013) · Brain · doi:10.1093/brain/awt192 · Cited by 1,286
Self-citationKordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251
Self-citationLang, A. E., Gill, S., Patel, N. K., Lozano, A., Nutt, J. G., Penn, R., Brooks, D. J., Hotton, G., Moro, E., Heywood, P., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20737 · Cited by 983
Self-citationFunctional recovery in parkinsonian monkeys treated with GDNF
Gash, D. M., Zhang, Z., Ovadia, A., Cass, W. A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P. A., Collins, F., et al. (1996) · Nature · doi:10.1038/380252a0 · Cited by 955
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
Nutt, J. G., Burchiel, K. J., Comella, C. L., Jankovic, J., Lang, A. E., Laws, E. R., Lozano, A. M., Penn, R. D., Simpson, R. K., Stacy, M., et al. (2003) · Neurology · doi:10.1212/wnl.60.1.69 · Cited by 824
Self-citationNeurturin, a relative of glial-cell-line-derived neurotrophic factor
Kotzbauer, P. T., Lampe, P. A., Heuckeroth, R. O., Golden, J. P., Creedon, D. J., Johnson Jr, E. M., & Milbrandt, J. (1996) · Nature · doi:10.1038/384467a0 · Cited by 710
Marks, W. J., Bartus, R. T., Siffert, J., Davis, C. S., Lozano, A., Boulis, N., Vitek, J., Stacy, M., Turner, D., Verhagen, L., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70254-4 · Cited by 684
Self-citationMarks, W. J., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., Taylor, R., Cahn-Weiner, D. A., Stoessl, A. J., Olanow, C. W., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70065-6 · Cited by 596
Self-citationChung, C. Y., Koprich, J. B., Siddiqi, H., & Isacson, O. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5427-08.2009 · Cited by 391
α-Synuclein–Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons
Decressac, M., Kadkhodaei, B., Mattsson, B., Laguna, A., Perlmann, T., & Björklund, A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004676 · Cited by 290
Cited by
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859
“However, multiple clinical trials, including 2 phase II trials, failed to meet the primary endpoint.(284) Uncertainty remains about the potential efficacy of trophic factors in PD.”
Self-citationLang, A. E., & Espay, A. J. (2018) · Movement Disorders · doi:10.1002/mds.27360 · Cited by 370
Self-citationCurrent and experimental treatments of Parkinson disease: A guide for neuroscientists
Oertel, W., & Schulz, J. B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13750 · Cited by 369
Mehta, A. M., Sonabend, A. M., & Bruce, J. N. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0520-4 · Cited by 331
Emerging therapies in Parkinson disease — repurposed drugs and new approaches
Elkouzi, A., Vedam-Mai, V., Eisinger, R. S., & Okun, M. S. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0155-7 · Cited by 300
Metadata
- Authors
- Warren Olanow, C., Bartus, R. T., Baumann, T. L., Factor, S., Boulis, N., Stacy, M., Turner, D. A., Marks, W., Larson, P., Starr, P. A., Jankovic, J., Simpson, R., Watts, R., Guthrie, B., Poston, K., Henderson, J. M., Stern, M., Baltuch, G., Goetz, C. G., Herzog, C., Kordower, J. H., Alterman, R., Lozano, A. M., & Lang, A. E.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2015-06-10
- Volume
- 78
- Issue
- 2
- Pages
- 248-257
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1494864007
- Cited by
- 287
- References
- 25
- FWCI
- 19.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double‐blind, randomized, controlled trial. https://app.cochat.ai/papers/10.1002/ana.24436
- The paper
- Warren Olanow, C., Bartus, R. T., Baumann, T. L., Factor, S., Boulis, N., Stacy, M., Turner, D. A., Marks, W., Larson, P., Starr, P. A., Jankovic, J., Simpson, R., Watts, R., Guthrie, B., Poston, K., Henderson, J. M., Stern, M., Baltuch, G., Goetz, C. G., . . . Lang, A. E. (2015). Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double‐blind, randomized, controlled trial. Annals of Neurology. https://doi.org/10.1002/ana.24436
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.